Design suppressor drugs targeting tRF-3021a to down-regulate the expression of ADAM10 protein, maintain the expression of membrane protein MICA, reduce soluble MICA, and remove the immune escape of tumor cells to NK cells. Here, ADAM10 is linked to neoplasm.